Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Swift

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Current Pharmaceutical Design|June 22, 2006
The renal epithelial sodium channel: genetic heterogeneity and implications for the treatment of high blood pressureG A Sagnella, P A Swift
International Journal of Clinical Practice|August 19, 2010
Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence requiredP A Swift, P A Andrews
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|March 7, 2002
Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockersP A Swift, G A MacGregor
Lancet (London, England)|May 30, 2001
Cocaine use and acute left ventricular dysfunctionC G Missouris, P A Swift, D R Singer
Neuropharmacology|December 1, 1988
Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in miceR G Pertwee, S G Greentree, P A Swift
Journal of Pharmaceutical Sciences|December 1, 1987
Substituted spiro[isoxazolidine-3,2'-tricyclo[3.3.1.1(3,7)]decane] derivativesG B Mullen, P A Swift, V S Georgiev
Chemotherapy|January 1, 1989
Studies on antifungal agents. 20. Effect of the nitrogen substitution on the in vitro activity of novel 3,5-substituted isoxazolidinesP A Swift, G B Mullen, J T Mitchell, et al.
Arzneimittel-Forschung|February 1, 1990
Studies on antifungal agents. Novel cis-5-alkyl (or alkenyl)-3-phenyl-3-(1H-azol-1-ylmethyl)-2-methyl-isoxazolidine derivativesG A Bennett, P A Swift, G B Mullen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
In vitro antifungal activity of novel substituted 3,5-diphenyl-3-(1H-1,2,4-triazol-1-ylmethyl)-2- methylisoxazolidine derivativesG A Bennett, P A Swift, G B Mullen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
Synthesis and antifungal activity of novel isoxazolidine compoundsG B Mullen, P A Swift, G A Bennett, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Pharmaceutical Design|June 22, 2006
The renal epithelial sodium channel: genetic heterogeneity and implications for the treatment of high blood pressureG A Sagnella, P A Swift
International Journal of Clinical Practice|August 19, 2010
Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence requiredP A Swift, P A Andrews
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|March 7, 2002
Renoprotection in Type 2 diabetes: blockade of the renin-angiotensin system with angiotensin II receptor blockersP A Swift, G A MacGregor
Lancet (London, England)|May 30, 2001
Cocaine use and acute left ventricular dysfunctionC G Missouris, P A Swift, D R Singer
Neuropharmacology|December 1, 1988
Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in miceR G Pertwee, S G Greentree, P A Swift
Journal of Pharmaceutical Sciences|December 1, 1987
Substituted spiro[isoxazolidine-3,2'-tricyclo[3.3.1.1(3,7)]decane] derivativesG B Mullen, P A Swift, V S Georgiev
Chemotherapy|January 1, 1989
Studies on antifungal agents. 20. Effect of the nitrogen substitution on the in vitro activity of novel 3,5-substituted isoxazolidinesP A Swift, G B Mullen, J T Mitchell, et al.
Arzneimittel-Forschung|February 1, 1990
Studies on antifungal agents. Novel cis-5-alkyl (or alkenyl)-3-phenyl-3-(1H-azol-1-ylmethyl)-2-methyl-isoxazolidine derivativesG A Bennett, P A Swift, G B Mullen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
In vitro antifungal activity of novel substituted 3,5-diphenyl-3-(1H-1,2,4-triazol-1-ylmethyl)-2- methylisoxazolidine derivativesG A Bennett, P A Swift, G B Mullen, et al.
Annals of the New York Academy of Sciences|January 1, 1988
Synthesis and antifungal activity of novel isoxazolidine compoundsG B Mullen, P A Swift, G A Bennett, et al.
Pageof 2